Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Cytochrome P450 2C9 Inducers [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
ENZALUTAMIDE 49,270 9,676 19.6% 9,282 576 76.0 yrs 0.6%
CARBAMAZEPINE 24,577 2,156 8.8% 9,608 1,705 50.1 yrs 61.8%
BOSENTAN 19,581 4,346 22.2% 8,862 303 52.5 yrs 73.2%
DABRAFENIB 19,305 4,165 21.6% 5,325 500 58.3 yrs 48.0%
PHENYTOIN 14,469 1,449 10.0% 5,241 1,087 46.5 yrs 50.7%
RITONAVIR 11,980 1,190 9.9% 2,925 350 43.8 yrs 43.8%
APREPITANT 5,620 1,195 21.3% 2,917 1,170 52.8 yrs 70.9%
SPARSENTAN 3,280 18 0.5% 209 2 49.3 yrs 43.8%
IVOSIDENIB 1,695 121 7.1% 505 52 67.9 yrs 47.9%
LETERMOVIR 1,416 252 17.8% 398 50 46.6 yrs 42.7%

Head-to-Head Comparisons

ENZALUTAMIDE vs CARBAMAZEPINE ENZALUTAMIDE vs BOSENTAN ENZALUTAMIDE vs DABRAFENIB ENZALUTAMIDE vs PHENYTOIN CARBAMAZEPINE vs BOSENTAN CARBAMAZEPINE vs DABRAFENIB CARBAMAZEPINE vs PHENYTOIN BOSENTAN vs DABRAFENIB BOSENTAN vs PHENYTOIN DABRAFENIB vs PHENYTOIN
← Back to Cytochrome P450 2C9 Inducers [MoA] Class side effects →